SEER icon

Seer Inc

2.05 USD
-0.01
0.49%
At close Updated Sep 12, 4:00 PM EDT
Pre-market
After hours
2.05
0.00
0%
1 day
-0.49%
5 days
-1.91%
1 month
-6.82%
3 months
-3.76%
6 months
2.5%
Year to date
-12.02%
1 year
25%
5 years
-96.37%
10 years
-96.37%
 

About: Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.

Employees: 134

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

27% more capital invested

Capital invested by funds: $46.6M [Q1] → $59M (+$12.4M) [Q2]

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

1% more funds holding

Funds holding: 67 [Q1] → 68 (+1) [Q2]

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

0.98% more ownership

Funds ownership: 49.41% [Q1] → 50.39% (+0.98%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

Financial journalist opinion

Based on 3 articles about SEER published over the past 30 days

Neutral
Seeking Alpha
5 days ago
Seer, Inc. (SEER) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Seer, Inc. (NASDAQ:SEER ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Omid Farokhzad - Founder, CEO, & Chair of the Board of Directors Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley.
Seer, Inc. (SEER) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral
GlobeNewsWire
12 days ago
Seer Appoints Isaac Ro to its Board of Directors
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors.
Seer Appoints Isaac Ro to its Board of Directors
Neutral
GlobeNewsWire
19 days ago
Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Neutral
Seeking Alpha
1 month ago
Seer, Inc. (SEER) Q2 2025 Earnings Call Transcript
Seer, Inc. (NASDAQ:SEER ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants David R. Horn - President,Treasurer & CFO Kelly Gura - Corporate Participant Omid C.
Seer, Inc. (SEER) Q2 2025 Earnings Call Transcript
Positive
The Motley Fool
1 month ago
Seer (SEER) Q2 Revenue Jumps 32%
Seer (SEER -2.83%), a life sciences technology firm specializing in advanced proteomics, released its second quarter results for fiscal 2025 on August 6, 2025. Seer reported GAAP revenue of $4.1 million, topping consensus estimates of $3.75 million by $0.35 million and marking a 32% increase from the prior-year period.
Seer (SEER) Q2 Revenue Jumps 32%
Neutral
Zacks Investment Research
1 month ago
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Seer, Inc. (SEER) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.35 per share a year ago.
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph ® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025.
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Neutral
GlobeNewsWire
1 month ago
Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA.
Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference
Neutral
GlobeNewsWire
1 month ago
Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
Positive
Zacks Investment Research
3 months ago
What Makes Seer, Inc. (SEER) a Strong Momentum Stock: Buy Now?
Does Seer, Inc. (SEER) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Seer, Inc. (SEER) a Strong Momentum Stock: Buy Now?
Charts implemented using Lightweight Charts™